Case Studies & Accomplishments

Timeline to validated antibody is comparable to single cell cloning, while still getting the cost-conscious advantages of hybridoma.  Furthermore, since antibody activity is first confirmed as a hybridoma, this approach boosts a high reproducibility rate of antigen binding (100% of parental wells cloned) compared to single cell cloning.

After less than 2 months, you can have monoclonal hybridomas, validated sequence, and recombinant antibodies to move forward.

Successful Green Mountain Antibodies Targets

Green Mountain Antibodies – Notable Successes

• Reagent antibodies for Pre-clinical and Clinical studies (ADA, PK, Tox, Neutralizing, functional evaluation)
• Small molecule therapeutic development studies (Zeljanz, Voriconazole, Azithromycin, Cortisol, cyclophosphamide)
• Functional antibodies (agonist, antagonist)
• Reagent antibodies for various assay platforms: immunohistochemistry, flow cytometry, Western analysis, immunoprecipitation, ELISA, MSD, Gyros, etc.
• Reagent antibodies for pharmacodynamics studies
• Reagent antibodies for evaluation of drug levels in sera (antibodies specific for parent drug over potential metabolites)
• Reagent antibodies that distinguish specific arms of bi-specific antibodies
• Antibodies for biotherapeutic candidate development
• Antibodies for diagnostic kit development
• Reagent antibodies for quality control evaluation of marketed drug products
• Internal product line development